(2R,3R,4S,5R,6R)-2-[(2R)-2-[(2S,3R,4R)-4,5-Dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]-2-hydroxyethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:155639

Synonyms

beta-D-galacto-hexopyranosyl-(1->3)-[beta-D-galacto-hexopyranosyl-(1->6)]-D-galacto-hexofuranose
Gal(b1-3)[Gal(b1-6)]Galf
WURCS=2.0/2,3,2/[a2112h-1x_1-4][a2112h-1b_1-5]/1-2-2/a3-b1_a6-c1

Definition

References

GlyGen:G99263WY
GlyTouCan:G99263WY

Ontology

ChEBI ( EBI )

Relationships

is a type of: glycoside

glycoside Show first 5 Terms

Phenotype

Phenotype resulting from (2R,3R,4S,5R,6R)-2-[(2R)-2-[(2S,3R,4R)-4,5-Dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]-2-hydroxyethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (2R,3R,4S,5R,6R)-2-[(2R)-2-[(2S,3R,4R)-4,5-Dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]-2-hydroxyethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (2R,3R,4S,5R,6R)-2-[(2R)-2-[(2S,3R,4R)-4,5-Dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]-2-hydroxyethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model